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The study of the epigenetic regulation of drug-metabolizing enzymes that might affect drug response and adverse drug reactions is important for understanding individual differences in drug response, drug metabolism and pharmacokinetics. Epigenetic modifications include transcriptional (DNA methylation and histone modification) and post-transcriptional (microRNA (miRNA) and ubiquitination) regulation, affecting phenotypic changes. Because of their dynamic nature, epigenetic factors provide a link between the genome and the phenotypic outcomes, and fill the gap between genome and proteins. Recently, among these epigenetic factors, miRNAs have been studied most extensively.
MiRNAs are a large family of non-coding RNAs that are evolutionarily conserved, endogenous, and 21-23 nucleotides in length. MiRNAs regulate gene expression by targeting messenger RNAs (mRNAs) by binding to complementary regions of transcripts to repress their translation or mRNA degradation. MiRNAs are encoded by the genome, and more than 2,000 human miRNAs have been identified so far. In silico prediction estimates that ³60% of human mRNAs could be targets of miRNAs. Similar to mRNA, miRNAs are expressed in a tissue-or cell-specific manner. MiRNAs can potentially regulate every aspect of cellular processes such as differentiation, proliferation, apoptosis and necrosis as well as a wide range of physiological processes. Although miRNA research into the metabolism of xenobiotics/ endobiotics is still in its infancy, understanding of miRNAs is progressing rapidly. Recently, many reports concerning miRNAs related to cancer have been published; however, the miRNA research into the metabolism of xenobiotics and endobiotics has only recently been instigated.
The expression of drug-and xenobiotic-metabolizing enzymes and nuclear receptors and their regulation by miRNAs could be important factors for the outcomes of drug response and adverse drug reactions. The different profiles of the expression of P450 isoenzymes determine the amount of reactive intermediates formed and the resulting adverse drug response. The mechanisms of the transcriptional regulation of P450 and P450-related nuclear receptors have been considerably clarified, but the post-transcriptional regulation largely remains to be elucidated. Recently, various P450s and nuclear receptors have been found to be posttranscriptionally regulated by miRNAs as summarized in Table 1 . For example, we reported that miR-148a regulates pregnane X receptor (PXR) but not CYP3A4. Notably, the miR-148a-dependent regulation of PXR affected the induction of endogenous CYP3A4 in human LS180 cells. Correlation analysis using human liver samples showed that the CYP3A4 protein level showed a significantly positive correlation with the CYP3A4 mRNA level. The PXR protein level was also correlated with CYP3A4 protein level. However, the PXR protein level was not correlated with the PXR mRNA level, indicating the post-transcriptional regulation. The transcriptional efficiency of PXR was inversely correlated with the miR-148a levels. Although more precise and quantitative investigations are needed, miR-148a-dependent PXR regulation would have great impact on the large inter-individual variability of CYP3A4 expression in human livers. Collectively, the regulation of nuclear receptors by miRNAs results in changes in the expression of a variety of target genes, constructing complex networks. Further studies will clarify the significance of miRNAs in the control of pharmacokinetics and the mechanism of interand intra-individual differences in drug responses and adverse drug reactions.
SNPs (single nucleotide polymorphisms) occur in an average of 1/1000 bases in the human genome, and are present not only in the mRNA but also in mature miRNA sequences. SNPs in miRNAs could modify various biological processes by influencing the processing or target selection of miRNAs. Only ³10% of human precursor (pre)-miRNAs have documented SNPs and <1% of miRNAs have SNPs in the functional seed sequence region. A SNP [rs7372209] in the primary (pri)-miR26a gene and a SNP [rs1834306] in the pri-miR-100 gene were significantly associated with the tumor response or time to progression in 61 metastatic colorectal cancer patients treated with 5-fluorouracil and CPT-11, suggesting a relationship between the clinical outcome of drug therapy and SNPs in the miRNA-biogenesis machinery, but the molecular mechanisms by which these polymorphisms act have not yet been clarified. Although seed sequence variations in miRNAs Drug Metab. Pharmacokinet. 28 (1): 1-2 (2013). Copyright © 2013 by the Japanese Society for the Study of Xenobiotics (JSSX) seem to be very rare, they have the potential to influence the expression of many genes and related pathways. Compared to the very low frequency of SNPs in the functional regions of miRNAs, a considerable level of variation at the target sites is conceivable. Many miRNA target-related polymorphisms are reported to be associated with the phenotypes of diseases, because a gain-of-function or loss-of-function would result in changes in the expression of target mRNAs. However, actually, there are few examples regarding miRNA-related polymorphisms affecting the drug response and adverse reactions, such as human dehydrofolate reductase (DHFR) and sulfotransferase isoform 1A1 (SULT1A1). This new class of miRNA-related polymorphisms may contribute to the study of inter-individual differences in drug responses and adverse drug reactions.
A growing number of reports have shown that aberrant miRNA expression is a common feature of human diseases. A human miRNA-disease database (HMDD) is publicly accessible at this website: http://202/38/126.151/hmdd/mirna/md/. However, the patterns among the miRNA-disease associations remain largely unclear, miRNAs are now considered as a new tool for diagnosis and therapeutics. Our great concern is that the dysregulation of specific miRNAs in diseases or miRNA manipulation in clinical therapy may lead to changes in drug responses in patients. The most advanced miRNA-based therapeutics is targeted to the liverspecific miR-122, which is involved in hepatitis C replication and cholesterol metabolism. Since the expression changes of miRNA in cancer cells are reported to be associated with resistance to anticancer drugs, the miRNA-based therapeutics could be used to regulate drug sensitivity. An individual miRNA could regulate several target genes and signal pathways simultaneously; therefore, miRNA-based therapeutics may cause unanticipated effects via unknown targets genes and pathways.
Th discovery of circulating miRNA in body fluids, especially in plasma and urine, opens up the great possibility of using miRNAs as a sensitive, informative and non-invasive potential biomarker for drug induced adverse events. Many studies of circulating miRNA have already been conducted regarding the clinical diagnosis and prognosis of cancer, but few papers have been published in relation to drug metabolism and pharmacokinetics. Increased plasma concentrations of miR-122, miR-133a, and miR-124 corresponded to injuries or diseases in liver, muscle and brain, respectively, while each of these is the abundant and specific miRNA in each organ. The miR-122 concentration in plasma increased earlier than the increase of aminotransferase activities in the blood, and now is expected to be a therapeutic drug as well as a reliable biomarker. Although several challenges remain to be addressed, circulating miRNAs have great potential in our research fields.
We are now entering an interesting new era in which the contribution of miRNAs in controlling various pharmacological and toxicological outcomes will become more clear. As the methodologies for miRNA studies are now becoming more widespread, the comprehensive understanding of miRNAs will lead to progress in our research fields. In the near future, miRNA profiling may lead to the discovery of novel miRNA biomarkers that might improve the prediction of pharmacokineitcs, metabolic activation and detoxification of drugs in vivo in humans. In addition, the studies of miRNA functions will help to develop new concept drugs. 
